{"id":"angiotensin-ii-receptor-blockers","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Cough (less common than with ACE inhibitors)"}]},"_chembl":{"chemblId":"CHEMBL4303676","moleculeType":"Small molecule","molecularWeight":"1046.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ARBs selectively antagonize AT1 receptors on vascular smooth muscle and adrenal tissue, inhibiting the renin-angiotensin-aldosterone system (RAAS). This prevents angiotensin II-mediated vasoconstriction, sodium retention, and sympathetic activation, resulting in vasodilation and reduced blood pressure. ARBs are commonly used for hypertension management and have cardioprotective effects in heart failure and post-myocardial infarction patients.","oneSentence":"Angiotensin II Receptor Blockers (ARBs) block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:39.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction cardioprotection"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":"Diabetes Mellitus, High Blood Pressure, Cardiovascular Diseases","enrollment":9476},{"nctId":"NCT05168787","phase":"","title":"Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2020-08-13","conditions":"Heart Failure","enrollment":6558},{"nctId":"NCT07493603","phase":"PHASE1, PHASE2","title":"A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease","status":"RECRUITING","sponsor":"Xia Liang","startDate":"2026-01-16","conditions":"Coronary Heart Disease, Coronary Artery Disease, Atheroscleroses","enrollment":30},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT06797518","phase":"PHASE2","title":"Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-21","conditions":"Glomerulonephritis, IGA, Immunoglobulin A Nephropathy","enrollment":20},{"nctId":"NCT07185256","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)","status":"RECRUITING","sponsor":"Opus Genetics, Inc","startDate":"2025-09-25","conditions":"ARB, BVMD, Autosomal-Dominant Bestrophinopathy","enrollment":10},{"nctId":"NCT07483151","phase":"","title":"Venous Congestion And Cognitive Dysfunction After Cardiac Surgery","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-11-01","conditions":"Intraoperative Venous Congestion And Cognitive Dysfunction After Cardiac Surgery","enrollment":110},{"nctId":"NCT05457283","phase":"PHASE3","title":"A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-11-08","conditions":"Chronic Kidney Disease, Proteinuria, Children","enrollment":100},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT04789733","phase":"NA","title":"The GUARDIAN Pilot Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2021-04-27","conditions":"General Surgery","enrollment":80},{"nctId":"NCT07465666","phase":"","title":"A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-01","conditions":"Hypertension","enrollment":500},{"nctId":"NCT06975111","phase":"PHASE2, PHASE3","title":"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-03-01","conditions":"Menopause, Menopause Hot Flashes, Menopause Related Conditions","enrollment":200},{"nctId":"NCT04456816","phase":"PHASE2","title":"A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2020-08-31","conditions":"Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy","enrollment":23},{"nctId":"NCT07447206","phase":"PHASE2","title":"Vascular Intervention Strategies Trial for Alzheimer's","status":"NOT_YET_RECRUITING","sponsor":"University of Southern California","startDate":"2026-03","conditions":"Hypertension, Hypercholesterolemia, Dementia Risk Factors","enrollment":10},{"nctId":"NCT06578078","phase":"PHASE3","title":"A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2024-10-03","conditions":"Heart Failure, Chronic Kidney Diseases","enrollment":94},{"nctId":"NCT07157787","phase":"PHASE2","title":"Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-09-19","conditions":"Primary Membranous Nephropathy","enrollment":30},{"nctId":"NCT07167368","phase":"NA","title":"Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients","status":"RECRUITING","sponsor":"Haiyan Pan","startDate":"2025-09-15","conditions":"Cardiorenal Syndrome","enrollment":60},{"nctId":"NCT06128980","phase":"PHASE2, PHASE3","title":"Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy","status":"RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2025-01-09","conditions":"Heart Failure With Reduced Ejection Fraction, Heart Rhythm Disorder","enrollment":348},{"nctId":"NCT07292493","phase":"","title":"Immune System in Diabetic Kidney Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Centre Ljubljana","startDate":"2025-12-01","conditions":"Diabetes, Diabetic Kidney Disease, Complement System","enrollment":90},{"nctId":"NCT03417388","phase":"PHASE4","title":"Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-09","conditions":"Coronary Artery Disease","enrollment":2476},{"nctId":"NCT07044700","phase":"","title":"Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2028-01-31","conditions":"Heart Failure of Reduced Ejection Fraction (HFrEF)","enrollment":5000},{"nctId":"NCT06526195","phase":"NA","title":"Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure","status":"RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2024-12-13","conditions":"Heart Failure, Heart Diseases, Cardiovascular Diseases","enrollment":850},{"nctId":"NCT01652209","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2013-09-01","conditions":"Acute Myocardial Infarction","enrollment":90},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT05196035","phase":"PHASE3","title":"A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-03-28","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":219},{"nctId":"NCT07376265","phase":"","title":"A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-20","conditions":"Heart Failure","enrollment":1249},{"nctId":"NCT05183646","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB","status":"RECRUITING","sponsor":"Dimerix Bioscience Pty Ltd","startDate":"2022-05-30","conditions":"FSGS","enrollment":286},{"nctId":"NCT06299514","phase":"NA","title":"RAFT - Pace &Ablate","status":"RECRUITING","sponsor":"Habib Khan","startDate":"2024-04-25","conditions":"Atrial Fibrillation, Heart Failure, Pacemaker","enrollment":600},{"nctId":"NCT03856632","phase":"PHASE4","title":"Liraglutide Effect in Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2019-03-18","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT07355023","phase":"NA","title":"AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","status":"RECRUITING","sponsor":"Tri-Service General Hospital","startDate":"2026-01-01","conditions":"Left Ventricular (LV) Systolic Dysfunction","enrollment":5000},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07356388","phase":"PHASE3","title":"FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan","status":"ACTIVE_NOT_RECRUITING","sponsor":"kewen Chen,MD","startDate":"2025-01-30","conditions":"Kidney Transplantation Recipients, Proteinuria Patients","enrollment":54},{"nctId":"NCT07348718","phase":"","title":"Rubix LS Diabetic Kidney Disease (DKD) Registry Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rubix LS","startDate":"2025-12-15","conditions":"Diabetic Kidney Disease (DKD)","enrollment":2000},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":"Renal Insufficiency, Chronic, Hyperkalemia","enrollment":1112},{"nctId":"NCT07315191","phase":"PHASE4","title":"Finerenone Therapy for Pediatric HSPN With Mild Proteinuria","status":"RECRUITING","sponsor":"Capital Institute of Pediatrics, China","startDate":"2025-06-13","conditions":"Henoch Schönlein Purpura Nephritis","enrollment":116},{"nctId":"NCT05834803","phase":"NA","title":"Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-06-26","conditions":"Renovascular Hypertension, Renovascular Hypertension With Renal Failure, Heart Failure","enrollment":80},{"nctId":"NCT06023576","phase":"PHASE2","title":"A Study of Blood Pressure Control During Cancer Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-08-18","conditions":"Breast Cancer, Cardiotoxicity","enrollment":130},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT07311109","phase":"NA","title":"A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-15","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":150},{"nctId":"NCT07285187","phase":"","title":"Venous Congestion And Delirium After Cardiac Surgery","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-11-01","conditions":"Intraoperative, Venous Congestion, Postoperative Delirium (POD)","enrollment":120},{"nctId":"NCT07295522","phase":"PHASE4","title":"Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2026-01-08","conditions":"Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":368},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT07261098","phase":"PHASE2","title":"The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2026-01-01","conditions":"Advanced Lung Cancer","enrollment":200},{"nctId":"NCT05106036","phase":"NA","title":"Preventing Cognitive Decline by Reducing BP Target Trial","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-07-11","conditions":"Cognitive Decline, Blood Pressure, Hypertension","enrollment":4000},{"nctId":"NCT06183437","phase":"PHASE4","title":"The STOP-MED CTRCD Trial","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-03-04","conditions":"Heart Failure, Cardiotoxicity, Cardiac Toxicity","enrollment":335},{"nctId":"NCT07110415","phase":"PHASE4","title":"Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction","status":"RECRUITING","sponsor":"SPH Qingdao Growful Pharmacetical Co.,Ltd","startDate":"2025-11-06","conditions":"Coronary Heart Disease, Cardiac Dysfunction","enrollment":2708},{"nctId":"NCT04023227","phase":"PHASE4","title":"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-10","conditions":"Chagas Disease, Heart Failure","enrollment":918},{"nctId":"NCT07232277","phase":"","title":"Venous Congestion and Cardiac Surgery-Associated Acute Kidney Injury","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-10-15","conditions":"Intraoperative, Venous Congestion, Cardiac Surgery-associated Acute Kidney Injury","enrollment":114},{"nctId":"NCT06862115","phase":"PHASE3","title":"The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery","status":"RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2025-03-01","conditions":"Myocardium; Injury, Perioperative/Postoperative Complications, Angiotensin-Converting-Enzyme Inhibitor","enrollment":156},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT03418961","phase":"PHASE3","title":"S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-11-01","conditions":"Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain","enrollment":491},{"nctId":"NCT05267262","phase":"PHASE2","title":"Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis","status":"COMPLETED","sponsor":"River 3 Renal Corp.","startDate":"2022-06-15","conditions":"Alport Syndrome, Focal Segmental Glomerulosclerosis","enrollment":43},{"nctId":"NCT06700213","phase":"","title":"Guideline Directed Medical Therapy in Patients With Heart Failure","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2023-09-22","conditions":"Heart Failure","enrollment":300},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT04753840","phase":"NA","title":"Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension","status":"RECRUITING","sponsor":"Henan Institute of Cardiovascular Epidemiology","startDate":"2021-07-03","conditions":"Hypertension","enrollment":90},{"nctId":"NCT05272878","phase":"PHASE3","title":"Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-22","conditions":"Acute Kidney Injury","enrollment":508},{"nctId":"NCT02472028","phase":"PHASE4","title":"Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":"Cerebrovascular Disorders","enrollment":820},{"nctId":"NCT07094984","phase":"NA","title":"Comparison of Three Interventions for Antibiotic-Resistant Bacteria (ARB) Decolonization From the Gastrointestinal Tract","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2024-12-31","conditions":"Drug Resistance, Bacterial, Antimicrobial Drug Resistance","enrollment":360},{"nctId":"NCT04884802","phase":"NA","title":"The GUARDIAN Trial","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-07-25","conditions":"Blood Pressure","enrollment":6254},{"nctId":"NCT06704633","phase":"PHASE4","title":"Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania","status":"NOT_YET_RECRUITING","sponsor":"Martin Rohacek","startDate":"2026-01-05","conditions":"Heart Failure","enrollment":238},{"nctId":"NCT03733145","phase":"PHASE4","title":"Angiotensin II in General Anesthesia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-10-03","conditions":"Hypertension","enrollment":32},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT05331144","phase":"PHASE2","title":"Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)","status":"RECRUITING","sponsor":"Rong Zhang","startDate":"2022-10-25","conditions":"Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline","enrollment":180},{"nctId":"NCT03738878","phase":"PHASE4","title":"Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-11-15","conditions":"Hypertension","enrollment":4},{"nctId":"NCT06150560","phase":"PHASE3","title":"A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-04-01","conditions":"Coarctation of Aorta, High Blood Pressure","enrollment":120},{"nctId":"NCT07098897","phase":"PHASE3","title":"To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2024-08-01","conditions":"IgA Nephropathy (IgAN)","enrollment":150},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":"Hypertension, Obesity","enrollment":198},{"nctId":"NCT05806138","phase":"PHASE2","title":"A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-07-17","conditions":"Breast Cancer, Cardiac Dysfunction","enrollment":21},{"nctId":"NCT04715568","phase":"PHASE4","title":"Secondhand Tobacco Smoke and Cardiovascular Disease","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-03-30","conditions":"Cardiovascular Diseases, Hypertension","enrollment":100},{"nctId":"NCT05237323","phase":"PHASE3","title":"Micophenolate Mofetil Versus Azathioprine in Myocarditis","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-10-01","conditions":"Lymphocytic Myocarditis (Disorder), Heart Failure, Dilated Cardiomyopathy","enrollment":50},{"nctId":"NCT01679132","phase":"NA","title":"BAROSTIM NEO Hypertension Pivotal Trial","status":"SUSPENDED","sponsor":"CVRx, Inc.","startDate":"2013-04-12","conditions":"Uncontrolled Hypertension","enrollment":10},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT04761120","phase":"","title":"Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study","status":"RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2021-02-01","conditions":"Mitral Regurgitation, Tricuspid Regurgitation, Valvular Heart Disease","enrollment":550},{"nctId":"NCT03354143","phase":"PHASE2","title":"Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-04-10","conditions":"Hypertension","enrollment":85},{"nctId":"NCT04864145","phase":"NA","title":"Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2021-05-21","conditions":"Aortic Valve Disease","enrollment":210},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":"Ischemic Cardiomyopathy","enrollment":158},{"nctId":"NCT07032116","phase":"","title":"YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1","status":"NOT_YET_RECRUITING","sponsor":"Liu Hongfang","startDate":"2025-08-01","conditions":"Diabetic Kidney Disease (DKD)","enrollment":4472},{"nctId":"NCT06143566","phase":"PHASE1, PHASE2","title":"Polypill for Prevention of Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-11","conditions":"Type 2 Diabetes, High Blood Pressure","enrollment":200},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT04899206","phase":"","title":"ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA","status":"WITHDRAWN","sponsor":"Sebastian Videla","startDate":"2021-04-12","conditions":"ACE Inhibitors, ARB, Hypertension","enrollment":""},{"nctId":"NCT06964217","phase":"","title":"Immediate Fracture Risk After Antihypertensive Drug Initiation","status":"NOT_YET_RECRUITING","sponsor":"Ajou University School of Medicine","startDate":"2025-06-01","conditions":"Hypertension, Fracture","enrollment":10000000},{"nctId":"NCT04491136","phase":"PHASE4","title":"Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-11","conditions":"Heart Failure","enrollment":201},{"nctId":"NCT03180450","phase":"PHASE1, PHASE2","title":"The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)","status":"SUSPENDED","sponsor":"Sclnow Biotechnology Co., Ltd.","startDate":"2025-12-31","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT06838416","phase":"","title":"Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-11-17","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease, Renal Function","enrollment":300},{"nctId":"NCT06693934","phase":"NA","title":"Jockey Club Precision Prevention Programme on Young Onset Diabetes","status":"RECRUITING","sponsor":"Juliana CN Chan","startDate":"2024-11-23","conditions":"Diabetes, Pre Diabetes, Hypertension","enrollment":9000},{"nctId":"NCT04525729","phase":"PHASE4","title":"Rituximab and RASi in Patients with IgAN","status":"COMPLETED","sponsor":"Nan Chen,MD","startDate":"2020-07-01","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT05021419","phase":"NA","title":"Efficacy of a Streamlined Heart Failure Optimization Protocol","status":"COMPLETED","sponsor":"The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust","startDate":"2022-07-17","conditions":"Heart Failure with Reduced Ejection Fraction, Chronic Heart Failure","enrollment":60},{"nctId":"NCT05572957","phase":"NA","title":"LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10-14","conditions":"Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block","enrollment":50},{"nctId":"NCT00429364","phase":"PHASE3","title":"Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2007-01","conditions":"Marfan Syndrome","enrollment":608},{"nctId":"NCT02378805","phase":"","title":"Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","status":"RECRUITING","sponsor":"University Hospital Goettingen","startDate":"1995-07","conditions":"Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease","enrollment":800},{"nctId":"NCT06851845","phase":"","title":"Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-02-01","conditions":"Kidney Diseases","enrollment":100},{"nctId":"NCT06450522","phase":"NA","title":"Post-Discharge Pharmacist-led Rapid Medication Optimization for Heart Failure (Post-Discharge PHARM-HF)","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2024-07-04","conditions":"Heart Failure with Reduced Ejection Fraction HFrEF","enrollment":12},{"nctId":"NCT04637152","phase":"PHASE2","title":"Sacubitril/Valsartan in Resistant Hypertension","status":"COMPLETED","sponsor":"Hospital Geral Roberto Santos","startDate":"2020-11-11","conditions":"Resistant Hypertension, Blood Pressure","enrollment":80},{"nctId":"NCT03122834","phase":"","title":"Effect of Genetic Polymorphism on the Clinical Outcome of Patients With Heart Failure","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-04-15","conditions":"Heart Failure","enrollment":246},{"nctId":"NCT06012487","phase":"PHASE1","title":"Correlates and Control of Blood Pressure Variability","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-05-01","conditions":"Blood Pressure Variability","enrollment":10},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT01623492","phase":"","title":"Eisenmenger Quality Enhancement Research Initiative","status":"COMPLETED","sponsor":"Actelion","startDate":"2012-07-01","conditions":"Pulmonary Arterial Hypertension","enrollment":193},{"nctId":"NCT02624050","phase":"NA","title":"Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2016-08-01","conditions":"Hypotension, Anesthesia","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3073,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["azilsartan","candesartan","eprosartan","Irbesartan","losartan"],"phase":"phase_3","status":"active","brandName":"Angiotensin II Receptor Blockers","genericName":"Angiotensin II Receptor Blockers","companyName":"Ottawa Heart Institute Research Corporation","companyId":"ottawa-heart-institute-research-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Angiotensin II Receptor Blockers (ARBs) block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction cardioprotection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}